

## Pharnext to Host Research and Development Day on October 13, 2020

Event to be held virtually as a live webcast

**PARIS, France, 08:30 a.m. CET, September 29, 2020 – Pharnext SA (FR0011191287 - ALPHA)**, an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today announced that it will host a research and development (R&D) day focused on the company’s development efforts related to its lead asset, PXT3003, in Charcot-Marie-Tooth disease type 1A (CMT1A) on Tuesday, October 13, 2020, from 8:00 – 10:30 a.m. ET / 2:00 – 4:30 p.m. CET.

Highlights of the event will include:

- **CMT1A disease overview** including pathophysiology, disease burden and treatment expectations
- **CMT1A patient perspective** related to quality of life and challenges
- **Overview of PXT3003’s** clinical development and regulatory progress
- **PLEOTHERAPY platform** process flow and potential in drug development

In addition to Pharnext’s management team - Dr David Horn Solomon, CEO and Dr Adrian Hepner, CMO and Head of R&D - featured presenters include:

- **Mario Saporta MD, PhD, MBA, FAAN**, Associate Professor of Neurology & Human Genetics, Miller School of Medicine, University of Miami; Director, Charcot-Marie-Tooth Center of Excellence at the MDA care center, University of Miami
- **Allison Moore**, Founder and CEO, Hereditary Neuropathy Foundation

The event will conclude with a panel discussion involving the guest speakers together with Pharnext senior management and will provide an opportunity for Q&A.

All people interested, including equity research analysts, in attending the event may contact Janhavi Mohite at [janhavi.mohite@sternir.com](mailto:janhavi.mohite@sternir.com)

### Virtual Event Details

The virtual presentation will be webcast beginning at 8:00 a.m. ET / 2:00 p.m. CET on Tuesday, October 13, 2020, and may be accessed by visiting the “Investors” section of the Pharnext website.

### About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status



in Europe and the United States. PXT864 has generated encouraging Phase II results in Alzheimer's disease. Pharnext has developed a new drug discovery paradigm based on big genomics data and artificial intelligence: PLEOTHERAPY™. Pharnext identifies and develops synergic combinations of drugs called PLEODRUG™. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics, and is supported by a world-class scientific team. More information at [www.pharnext.com](http://www.pharnext.com).

Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).

## Contacts

### Pharnext

David Solomon  
Chief Executive Officer  
[contact@pharnext.com](mailto:contact@pharnext.com)  
+33 (0)1 41 09 22 30

### Media Relations (International)

Consilium Strategic Communications  
Mary-Jane Elliott  
Sukaina Virji  
Melissa Gardiner  
[pharnext@consilium-comms.com](mailto:pharnext@consilium-comms.com)

### Media Relations (U.S.)

Rooney Partners LLC  
Jeffrey Freedman  
[jfreedman@rooneyco.com](mailto:jfreedman@rooneyco.com)  
+1 646 432 0191  
+1 914 217 4124

### Media Relations (Europe)

Ulysse Communication  
Bruno Arabian  
+33 (0)6 87 88 47 26  
[barabian@ulyse-communication.com](mailto:barabian@ulyse-communication.com)  
Pierre-Louis Germain  
+33 (0)6 64 79 97 51  
[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com)  
+33 (0)1 81 70 96 30

### Investors Relations (U.S.)

Stern Investor Relations, Inc.  
Janhavi Mohite  
[janhavi.mohite@sternir.com](mailto:janhavi.mohite@sternir.com)  
+1 212 362 1200

### Financial Communication (Europe)

Actifin  
Stéphane Ruiz  
[sruiz@actifin.fr](mailto:sruiz@actifin.fr)  
+33 (0)1 56 88 11 15